-
PDF
- Split View
-
Views
-
Cite
Cite
K Yamaji, H Kohjitani, H Watanabe, M Taniwaki, R Akashi, S Kubo, H Ohira, Y Numasawa, M Arikawa, M Iwama, T Kitai, Y Kobayashi, T Tomohisa, Y Yamaji, K Ono, PREDICTOR, Plaque phenotyping using deep learning in optical coherence tomography imaging, European Heart Journal, Volume 45, Issue Supplement_1, October 2024, ehae666.2345, https://doi.org/10.1093/eurheartj/ehae666.2345
- Share Icon Share
Abstract
Artificial intelligence (AI) techniques have emerged as powerful tools in various computer vision tasks, particularly in classification, detection, and segmentation.
This study aimed to develop a deep learning model for categorizing optical coherence tomography (OCT) frames into different plaque phenotypes, including thin-cap fibroatheroma (TCFA) and fibroatheroma.
A prospective multicenter observational study enrolled 168 patients who underwent percutaneous coronary intervention (PCI) and received OCT imaging for non-target lesions with angiographically estimated diameter stenosis greater than 30% (177 vessels). Among them, 129 patients (135 vessels) underwent follow-up OCT imaging at 1 year. A total of 45,072 OCT frames were randomly divided into training and validation sets in a 4:1 ratio. An EfficientNet-B3 convolutional neural network model was developed to classify OCT frames into TCFA, thick-cap fibroatheroma, non-fibroatheroma, adaptive intimal thickening, and normal vessel categories.
A confusion matrix comparing manually assessed plaque phenotypes with AI-predicted phenotypes was presented in Table. In the validation datasets (9,015 frames), the overall accuracy of the model was 85.1%. For predicting the presence of TCFA, sensitivity was 81.1%, specificity was 98.8%, positive predictive value was 63.9%, and negative predictive value was 99.5%. Regarding the presence of fibroatheroma, sensitivity was 90.3%, specificity was 89.4%, positive predictive value was 93.1%, and negative predictive value was 85.4%.
Author notes
Funding Acknowledgements: Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): This research received funding from Abbott Medical Japan LLC, and finances were managed by Micron, Inc. Part of the research was supported by the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI; No. 22K08202).